<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586142</url>
  </required_header>
  <id_info>
    <org_study_id>NMRPG890041</org_study_id>
    <nct_id>NCT02586142</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin Injections by Ultrasounds Guidance and Stretching Exercise in Spastic Toe Clawing</brief_title>
  <official_title>Botulinum Toxin Injections by Ultrasounds Guidance and Stretching Exercise in Spastic Toe Clawing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Claw toes deformity result in spasticity often seem in patients with central nerve disease.
      It also cause pressure sore in foot and pain during walking that didn't well improve under
      traditional treatment. There are few relative reports about the Botulinum toxin type A
      (BTX-A) injection on claw toe. The investigators' study has two main purposes:

        1. assess the efficiency of BTX-A injection under ultrasonographyic guidance on improving
           lower extremities function, pain and spasticity in patients with symptomatic claw toes.

        2. assess if regular stretching exercise can strength the efficiency of BTX-A injection on
           improving lower extremities function, pain and spasticity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will enroll 50 hemiplegic stroke patients met the inclusion criteria(onset
      more than 6 month, lower extremity Brunnstrome stage more than stage IV, walking without
      assistance devices and pain during walking due to claw toe. The investigators will focus and
      inject BTX-A with ultrasonographyic guidance on flexor digitorum longus and brevis(both 50
      unit). If patients combine ankle plantar flexors spasticity, the investigators will inject
      another 50 unit on both the medial and lateral head of gastrocnemius . Every patients will
      receive regular stretching exercise in hospital and do self stretching exercise at home for 3
      months after injection. Patients will be evaluated at 2 weeks, 4 weeks and 12 weeks, 24 weeks
      and 1 year after injection. Outcome measure include severity of spasticity and pain, sensory
      and motor function, range of motion, functional assessment of lower extremity and analyze
      pressure under foot.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spasticity severity scale</measure>
    <time_frame>Change from Baseline data at 1 year</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection 0=none, 1=mild, 2= median, 3=severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensory function scale</measure>
    <time_frame>Change from Baseline data at 1 year</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection 0=no feeling, 1=abnormal, 2= normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brunnstrome stage</measure>
    <time_frame>Change from Baseline data at 1 year</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manual muscle test</measure>
    <time_frame>Change from Baseline data at 1 year</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection including toe flexion/ extension, ankle plantar flexion/ dorsiflexion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional ambulation classification scale</measure>
    <time_frame>Change from Baseline data at 1 year</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active range of motion measured by goniometer</measure>
    <time_frame>Change from Baseline data at 1 year</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Ashworth scale(MAS)</measure>
    <time_frame>Change from Baseline data at 1 year</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain severity measurement recorded by VAS</measure>
    <time_frame>Change from Baseline data at 1 year</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection 0=no pain; 100=maximum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To develop a questionnaire (ABILOCO questionnaire)</measure>
    <time_frame>Change from Baseline data at 1 year</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection.
Its a Rasch-built 13-item questionnaire to assess locomotion ability in stroke patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Berg Balance test</measure>
    <time_frame>Change from Baseline data at 1 year</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Get up and go test</measure>
    <time_frame>Change from Baseline data at 1 year</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10-meter walking test</measure>
    <time_frame>Change from Baseline data at 1 year</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fugl-Meyer Assessment</measure>
    <time_frame>Change from Baseline data at 1 year</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>Change from Baseline data at 1 year</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walking test</measure>
    <time_frame>Change from Baseline data at 1 year</time_frame>
    <description>patients will be evaluated at 4 weeks, 8 weeks, 12 weeks, 24 weeks and 1 year after injection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cerebrovascular Accident</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin type A(BTX-A) injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To inject Botulinum toxin type A on the spasticity lower extremities for participants by ultrasounds guidance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BTX-A injection plus stretching exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inject Botulinum toxin type A on the spasticity lower extremity for participants by ultrasounds guidance. After injection, arrange them to receive stretching exercise in Kaoshiung Chang Gung Memorial Hospital 3 time per week for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by ultrasounds guidance.</description>
    <arm_group_label>Botulinum toxin type A(BTX-A) injection</arm_group_label>
    <arm_group_label>BTX-A injection plus stretching exercise</arm_group_label>
    <other_name>Botulinum toxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stretching exercise</intervention_name>
    <description>After accepting Botulinum toxin type A injection, participants will be arranged to receive stretch exercise in Kaohsiung Chang Gung Memorial Hospital 3 times per week, for 3 month.</description>
    <arm_group_label>BTX-A injection plus stretching exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with spasticity toe clawing(metatarsophalange jointextension, proximal and
             distal phalange joint flexion)

          -  MAS scale of metatarsophalange joint and interphalangeal joint more than 2

          -  Pain during walking, abnormal gait patterns and can't wear shoess due to claw toe

          -  Haven't received botox or phenol or alcohol injections before

        Exclusion Criteria:

          -  Lower extremities joint contrature, bone deformity

          -  Had received botox injections or phenol injections or before due to lower extremities
             spasticity

          -  Combine other neuromuscular system disease

          -  Severe cognition disorder or aphasia after stroke

          -  Significant atrophy of flexor digitorum longus and brevis

          -  Allergy to botox

          -  Infection on injection site

          -  Have systemic infection

          -  Now accept aminioglycoside or other medicine will affect neuromusclar transition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pong Ya-Ping, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rehabilitation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Yelnik AP, Bonan IV. [Post stroke hemiplegia: lower limb benefit from botulinum toxin (review)]. Ann Readapt Med Phys. 2003 Jul;46(6):281-5. Review. French.</citation>
    <PMID>12928130</PMID>
  </reference>
  <reference>
    <citation>Rivera-Dominguez M, DiBenedetto M, Frisbie JH, Rossier AB. Pes cavus and claw toes deformity in patients with spinal cord injury and multiple sclerosis. Paraplegia. 1979 Feb;16(4):375-82.</citation>
    <PMID>431969</PMID>
  </reference>
  <reference>
    <citation>Mizel MS, Yodlowski ML. Disorders of the Lesser Metatarsophalangeal Joints. J Am Acad Orthop Surg. 1995 May;3(3):166-173.</citation>
    <PMID>10790665</PMID>
  </reference>
  <reference>
    <citation>Feeney MS, Williams RL, Stephens MM. Selective lengthening of the proximal flexor tendon in the management of acquired claw toes. J Bone Joint Surg Br. 2001 Apr;83(3):335-8.</citation>
    <PMID>11341415</PMID>
  </reference>
  <reference>
    <citation>Boulton AJ. Pressure and the diabetic foot: clinical science and offloading techniques. Am J Surg. 2004 May;187(5A):17S-24S. Review.</citation>
    <PMID>15147987</PMID>
  </reference>
  <reference>
    <citation>Myerson MS, Shereff MJ. The pathological anatomy of claw and hammer toes. J Bone Joint Surg Am. 1989 Jan;71(1):45-9.</citation>
    <PMID>2913002</PMID>
  </reference>
  <reference>
    <citation>Truckenbrodt H, HÃ¤fner R, von Altenbockum C. Functional joint analysis of the foot in juvenile chronic arthritis. Clin Exp Rheumatol. 1994 Sep-Oct;12 Suppl 10:S91-6. Review.</citation>
    <PMID>7955636</PMID>
  </reference>
  <reference>
    <citation>Cyphers SM, Feiwell E. Review of the Girdlestone-Taylor procedure for clawtoes in myelodysplasia. Foot Ankle. 1988 Apr;8(5):229-33.</citation>
    <PMID>3366427</PMID>
  </reference>
  <reference>
    <citation>Bernbach EH, Bernbach MR. A box joint arthrodesis for the proximal interphalangeal joint in claw toe deformity. J Am Podiatr Med Assoc. 1985 Nov;75(11):575-80.</citation>
    <PMID>4067859</PMID>
  </reference>
  <reference>
    <citation>Gracies JM, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part I: Local treatments. Muscle Nerve Suppl. 1997;6:S61-91. Review.</citation>
    <PMID>9826983</PMID>
  </reference>
  <reference>
    <citation>Gajiwala KJ, Sams SB, Pandya N, Wagh A. A new dynamic lumbrical simulating splint for claw hand deformity. Plast Reconstr Surg. 1991 Jan;87(1):170-3.</citation>
    <PMID>1984264</PMID>
  </reference>
  <reference>
    <citation>Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl. 1997;6:S92-120. Review.</citation>
    <PMID>9826984</PMID>
  </reference>
  <reference>
    <citation>O'Brien CF. Treatment of spasticity with botulinum toxin. Clin J Pain. 2002 Nov-Dec;18(6 Suppl):S182-90. Review.</citation>
    <PMID>12569967</PMID>
  </reference>
  <reference>
    <citation>Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):951-7. Review.</citation>
    <PMID>15201348</PMID>
  </reference>
  <reference>
    <citation>Korelitz BI, Sommers SC. Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes. Am J Gastroenterol. 1975 Nov;64(5):365-70.</citation>
    <PMID>2008</PMID>
  </reference>
  <reference>
    <citation>Stoquart GG, Detrembleur C, Palumbo S, Deltombe T, Lejeune TM. Effect of botulinum toxin injection in the rectus femoris on stiff-knee gait in people with stroke: a prospective observational study. Arch Phys Med Rehabil. 2008 Jan;89(1):56-61. doi: 10.1016/j.apmr.2007.08.131.</citation>
    <PMID>18164331</PMID>
  </reference>
  <reference>
    <citation>Lim EC, Ong BK, Seet RC. Botulinum toxin-A injections for spastic toe clawing. Parkinsonism Relat Disord. 2006 Jan;12(1):43-7. Epub 2005 Sep 29.</citation>
    <PMID>16198612</PMID>
  </reference>
  <reference>
    <citation>Suputtitada A. Local botulinum toxin type A injections in the treatment of spastic toes. Am J Phys Med Rehabil. 2002 Oct;81(10):770-5.</citation>
    <PMID>12362118</PMID>
  </reference>
  <reference>
    <citation>Chin TY, Nattrass GR, Selber P, Graham HK. Accuracy of intramuscular injection of botulinum toxin A in juvenile cerebral palsy: a comparison between manual needle placement and placement guided by electrical stimulation. J Pediatr Orthop. 2005 May-Jun;25(3):286-91.</citation>
    <PMID>15832139</PMID>
  </reference>
  <reference>
    <citation>Molloy FM, Shill HA, Kaelin-Lang A, Karp BI. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia. Neurology. 2002 Mar 12;58(5):805-7.</citation>
    <PMID>11889247</PMID>
  </reference>
  <reference>
    <citation>O'Brien CF. Injection techniques for botulinum toxin using electromyography and electrical stimulation. Muscle Nerve Suppl. 1997;6:S176-80. Review.</citation>
    <PMID>9826989</PMID>
  </reference>
  <reference>
    <citation>Berweck S, Schroeder AS, Fietzek UM, Heinen F. Sonography-guided injection of botulinum toxin in children with cerebral palsy. Lancet. 2004 Jan 17;363(9404):249-50.</citation>
    <PMID>14738817</PMID>
  </reference>
  <reference>
    <citation>Schroeder AS, Berweck S, Lee SH, Heinen F. Botulinum toxin treatment of children with cerebral palsy - a short review of different injection techniques. Neurotox Res. 2006 Apr;9(2-3):189-96. Review.</citation>
    <PMID>16785117</PMID>
  </reference>
  <reference>
    <citation>Sconfienza LM, Perrone N, Lacelli F, Lentino C, Serafini G. Ultrasound-guided injection of botulinum toxin A in the treatment of iliopsoas spasticity. J Ultrasound. 2008 Sep;11(3):113-7. doi: 10.1016/j.jus.2008.05.002. Epub 2008 Jul 3.</citation>
    <PMID>23396653</PMID>
  </reference>
  <reference>
    <citation>Rivest J, Lees AJ, Marsden CD. Writer's cramp: treatment with botulinum toxin injections. Mov Disord. 1991;6(1):55-9.</citation>
    <PMID>2005922</PMID>
  </reference>
  <reference>
    <citation>Critchfield J. Considering the immune response to botulinum toxin. Clin J Pain. 2002 Nov-Dec;18(6 Suppl):S133-41. Review.</citation>
    <PMID>12569960</PMID>
  </reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <last_update_submitted>October 23, 2015</last_update_submitted>
  <last_update_submitted_qc>October 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spasticity</keyword>
  <keyword>claw toe</keyword>
  <keyword>ultrasounds guidance</keyword>
  <keyword>botulinum toxin</keyword>
  <keyword>stretching exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

